Daphnetin Capsule In the Treatment of VaScular COgnitive Impairment Without Dementia

NCT06507488

Status	RECRUITING
Phase	Not Applicable
Sponsor	First People's Hospital of Shenyang
Enrollment	206 participants

Key Eligibility Criteria

Inclusion (5)

- Be 50-80 years of age (both ends included)
- Have a complaint of cognitive impairment involving memory and/or other cognitive domains that has persisted for at least 3 months
- Have a cognitive level that is neither normal nor demented according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Criteria (DSM-V criteria , a Montreal Cognitive Assessment (MoCA scale) score \<26 and e18, and a Clinical Dementia Rating (CDR) scale score of e0.5 in at least one domain and an overall CDR score d1
- Have a cognitive level that is neither normal nor demented according to DSM-V criteria, a MoCA scale score \<26 and e18, and a CDR scale score of e0.5 in at least one domain and an overall CDR score d1
- Voluntarily participate in this study and sign an informed consent form.

Exclusion (15)

- Previously diagnosed dementia; vascular cognitive impairment not associated with a condition other than dementia that may affect cognition
- Acute stroke event within 6 months
- Previously diagnosed hereditary or inflammatory small vessel disease
- Presence of congenital mental retardation and severe neurological or psychiatric disorders
- Illiteracy or severe visual or hearing impairment, severe aphasia, and other factors that may preclude cooperation with neuropsychological evaluation

... and 10 more (see full listing online)

Locations (1 total)

Shenyang First People's Hospital, Shenyang, Liaoning, China

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.